Help Privacy Policy Disclaimer
  Advanced SearchBrowse




Journal Article

HLA-F*01:01 presents peptides with N-terminal flexibility and a preferred length of 16 residues.


Huyton,  Trevor
Department of Cellular Logistics, MPI for Biophysical Chemistry, Max Planck Society;

External Resource
No external resources are shared
Fulltext (public)

(Publisher version), 876KB

Supplementary Material (public)

(Supplementary material), 79KB

(Supplementary material), 219KB

(Supplementary material), 105KB

(Supplementary material), 99KB


Ho, G. G. T., Heinen, F. J., Huyton, T., Blasczy, R., & Bade-Döding, C. (2019). HLA-F*01:01 presents peptides with N-terminal flexibility and a preferred length of 16 residues. Immunogenetics, 51(5-6), 353-360. doi:10.1007/s00251-019-01112-1.

Cite as: http://hdl.handle.net/21.11116/0000-0003-B3C3-6
HLA-F belongs to the non-classical HLA-Ib molecules with a marginal polymorphic nature and tissue-restricted distribution. HLA-F is a ligand of the NK cell receptor KIR3DS1, whose activation initiates an antiviral downstream immune response and lead to delayed disease progression of HIV-1. During the time course of HIV infection, the expression of HLA-F is upregulated while its interaction with KIR3DS1 is diminished. Understanding HLA-F peptide selection and presentation is essential to a comprehensive understanding of this dynamic immune response and the molecules function. In this study, we were able to recover stable pHLA-F*01:01 complexes and analyze the characteristics of peptides naturally presented by HLA-F. These HLA-F-restricted peptides exhibit a non-canonical length without a defined N-terminal anchor. The peptide characteristics lead to a unique presentation profile and influence the stability of the protein. Furthermore, we demonstrate that almost all source proteins of HLA-F-restricted peptides are described to interact with HIV proteins. Understanding the balance switch between HLA-Ia and HLA-F expression and peptide selection will support to understand the role of HLA-F in viral pathogenesis.